文献速递前列腺增生与排尿功能障碍

分析膀胱过度活动症口服药物的可及性与费用:揭示差异

Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities.
PubMed 文献 · Urology · 2023-09-30

本研究对2022年第一季度美国 Medicare 处方药计划 formulary 数据进行了横断面分析,评估18种膀胱过度活动症(OAB)药物的自付费用、年度总费用及使用管理要求。结果显示不同覆盖阶段月费用差异明显,仿制抗胆碱能药年费用494至1452美元,β3受体激动剂米拉贝隆年费用1283美元。作者结论认为,即使药物被覆盖,也不等于价格可负担。

要点

  • 共分析5721个计划 formulary,覆盖18种OAB药物,米拉贝隆是唯一β3受体激动剂。
  • 仅14.3%计划对Vesicare口服液要求事前授权,米拉贝隆为0.1%。
  • 仿制抗胆碱能药年费用494至1452美元,米拉贝隆年费用1283美元。

核心结论

  • 作者评估了OAB药物的覆盖、自付费用、年度总费用和使用管理,旨在提高定价透明度;作者认为覆盖并不等同于价格可负担。

研究设计与样本

  • 对2022年第一季度美国联邦医疗保险与医疗补助服务中心处方药计划 formulary 数据进行横断面分析,识别FDA批准的OAB药物。

主要发现

  • 共分析5721个计划 formulary,涉及18种药物;米拉贝隆是唯一β3受体激动剂。
  • 仅Vesicare口服液(14.3%的计划)和米拉贝隆(0.1%)要求事前授权;选择性仿制抗胆碱能药要求阶梯治疗的比例为12.4%至43.3%,β3受体激动剂为0.6%。
  • 初始覆盖阶段抗胆碱能药月均费用59美元(灾难性阶段14美元;覆盖缺口阶段72美元),β3受体激动剂月均费用47美元(灾难性阶段26美元;覆盖缺口阶段129美元)。
  • 仿制抗胆碱能药年总费用从494美元(奥昔布宁速释)至1452美元(达非那新),品牌抗胆碱能药年总费用从1175美元(Toviaz缓释)至2198美元(Oxytrol);β3受体激动剂年总费用为1283美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report out-of-pocket costs associated with overactive bladder (OAB) medications among Medicare beneficiaries and the uninsured. METHODS: We performed a cross-sectional analysis of the Centers for Medicare & Medicaid Services Prescription Drug Plan Formulary Data (Q1-2022). FDA-approved medications for OAB were identified. We calculated out-of-pocket costs for Medicare beneficiaries in each Part D prescription benefit phase, average retail price, total yearly costs and discounted prices through cash-pay discount coupons (GoodRx) or online pharmacies like Mark Cuban Cost Plus Drug Company (MCCPDC). We also report plan utilization management requirements. RESULTS: We analyzed 5721 plan formularies for 18 medications. Mirabegron was the only beta-3 agonist (B3). Only Vesicare oral solution (14.3% of plans) and Mirabegron (0.1%) required prior authorization. Many plans required step therapy for selective generic anticholinergics (ACH) (12.4%-43.3%), while the B3 rarely required step therapy (0.6%). Monthly costs varied by coverage phase and averaged $59 for ACHs in the initial coverage phase ($14 in catastrophic; $72 in coverage gap). The monthly cost for the B3 averaged $47 in the initial coverage phase ($26 in catastrophic; $129 in coverage gap). The total yearly cost for generic ACHs ranged from $494 (oxybutynin IR) to $1452 (darifenacin) and the yearly cost for brand-name ACHs ranged from $1175 (Toviaz ER) to $2198 (Oxytrol). The total yearly cost for the B3 was $1283. CONCLUSION: We evaluated coverage, out-of-pocket costs, total yearly costs, and utilization management for OAB medications to make pricing more transparent. While selective medications may be "covered," coverage does not translate into affordable drug prices.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Shapiro K, Dusetzina SB, Brucker BM, et al. Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities. Urology. 2023. PMID: 37778479. doi:10.1016/j.urology.2023.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。